People In Business NYSE 3

USA

Jason L. Groves brings five-bagger value to Medifast 17 June 2018

NEWS BITES - PEOPLE IN BUSINESS

Jason L. Groves was appointed Executive Vice President of Medifast (NYSE:MED) three years ago on June 17, 2015. The present value of USD1,000 (PV1000) invested on the appointment date is $US5,365, for a capital gain of $US4,012 and dividend reinvested of $US353. In the same period the shares were up 401.2% from $US32.6 to $US163.3.

SECTION 1 BIOGRAPHY JASON L. GROVES, EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL

Jason L. Groves, Esq., age 46, has served as the Company's Executive Vice President and General Counsel since November 2011, and Corporate Secretary since June 2015. Mr. Groves was also a director of the Company from 2009 to 2015 and served as a member of the Executive Committee. Prior to joining Medifast in November 2011, Mr. Groves served as Assistant Vice President of Government Affairs for Verizon Maryland, since 2003. Mr. Groves is also a United States Army veteran. He was a direct commissioned Judge Advocate in the United States Army Judge Advocate General's Corp ("JAG"). As a JAG Officer, he practiced law and had the distinction of prosecuting criminal cases in the District Court of Maryland as a Special Assistant United States Attorney. Over the course of three years, he received two Army Achievement Medals, and one Army Commendation Medal. Mr. Groves also sits on several non-profit boards including Anne Arundel Medical Center and the Maryland Hospital Association. Mr. Groves received his Bachelor of Science degree, cum laude, in Business with a concentration in Hospitality Management, from Bethune-Cookman University. He also obtained his juris doctorate from North Carolina Central University School of Law and is a member of the New Jersey and District of Columbia bars as well as several bar associations.

SECTION 2 MEDIFAST, INC. PRICE PERFORMANCE SCORECARD (NYSE:MED):

2.1 Medifast, Inc. is placed 5/2,700 in the BSS News Bites ranking of price performance of NYSE stocks in the past year, a percentile ranking of 99.

2.2 The Past Three Years

Medifast accelerates rise, up 403% in 3 years

Medifast, Inc. (NYSE:MED), has strengthened $US130.89 (403.2%) over the past three years, compared with the S&P 500 Index which rose 695.2 points (33.4%) in the three years for a relative price increase of 369.9%. The shares extended their rise from 12.0c (0.4%) 2 years ago to $US10.05 (30.8%) a year ago. They accelerated their rise to $US120.72 (283.2%) in the past year to close at $US163.35 today.

2.3 MCap History:

Market Capitalization has increased by $US1.6 billion from $US393.1 million to $US2 billion since appointment.

MEDShare Price (USD)Market Capitalisation (USD)
Last Traded Jun 15163.352 billion
1 Year ago42.39505.3 million
2 Years ago32.58383.1 million
Jun 17, 201532.59393.1 million

2.4 Moving Annual Return (Trailing 12 months):

Based on a dynamic start date of 3 years ago, the Moving Annual Return has consistently exceeded 1.0%.

MEDCloseDividendsCapital Gain %% YieldAnnual Return %
Last Traded Jun 15$US163.35$US1.60283.23.8289.1
1 Year ago$US42.39$US1.1430.13.533.6
2 Years ago$US32.5850.0c0.41.51.9

Close 3 years ago $US32.46.

2.5 Present Value of $US1000 invested in the past

The present value of $US1000 invested a year ago is $US3,925

PV$10001-week1-month1-year
MED.NYSE1,0981,2693,925
S&P 500 Index1,0011,0191,143

2.6 Trailing Price Change %

1-Year price change of 283.2% for Medifast outperformed the change of 14.0% in the S&P 500 Index for a relative price change of 269.2%.

Price Change %1-Month3-Month1-Year
MED26.982.9283.2
Food products sector6.231.725.8
S&P 500 Index2.51.214.0

SECTION 3 MEDIFAST, INC. FINANCIALS AND GROWTH PERFORMANCE SCORECARD (NYSE:MED):

3.1 Key Financials (All figures percent)

Revenue Growth has improved from -4.3% in 2015 to 10.0% in 2017, Return on Equity has improved from 22.1% in 2015 to 25.5% in 2017 and Operating Margin has improved from 10.9% in 2015 to 13.4% in 2017.

MEDRevenue GrowthEPS GrowthOperating MarginROE
20171053.613.425.5
20160.4-99.918.6
2015-4.361.210.922.1

3.2 Growth

5-years average annualized earnings growth rate of 14.9%

+ Revenue growth rate has shown signs of recovery in recent years. [Year ended, all figures in %]

YearRevenue GrowthEPS GrowthEBITDA Growth
Dec 160.4-10.2-8.6
Dec 15-4.361.2-25.3
Dec 14-11.9-40.5-15.3

3.3 Revenue and Net Profit

In the last 5 years Compound Annual Growth Rate (CAGR) averaged -1.1% for Total Revenue and 11.8% for Net Profit.

DescriptionAnnual ($US M)5-year Avg ($US M)5-year CAGR %
Total Revenue302.3292.3-1.1
EBITDA40.336.82.5
Operating Profit40.333.610.5
Net Profit27.722.711.8

CAGR = Compound Annual Growth Rate

3.4 Performance (All figures in %)

Net Profit Margin 5-year average is 7.7% and Return on Equity 5-year average is 24.0%.

DescriptionAnnual5-year Avg
EBITDA Margin13.412.5
Operating Profit Margin13.411.5
Net Profit Margin9.27.7
Return on Equity25.524.0
Return on Assets19.017.8
Return on Capital Employed37.134.0

3.5 High Performance Indicators:

DescriptionValueRank In NYSE Market
Relative Price Change % (1 Year)269.2In Top 1%
3-mo Price Change %82.9In Top 2%
Return on Capital Employed [ROCE] %37.1In Top 3%
Return on Assets [ROA] %19In Top 4%
% Prem to 1-mo Vol Wtd Price10.9In Top 7%
Price Change %1.0In Top Quartile

SECTION 4 MEDIFAST, INC. GLOBAL RANK (NYSE:MED):

4.1 Global Rank

Global Rank [out of 47,580 stocks]

DescriptionValueRankQuartile
MCap (US$)2B5,524Top
Total Assets (US$)145.9M22,028Second
Revenue (US$)302.3M12,699Second
Net Profit (US$)27.7M10,625Top
Return on Equity %25.52,626Top
Net Profit Margin %9.212,505Second
Price to Book18.034,496Third
Price Earnings57.317,036Second
Yield %1.018,190Second
PV$1000 (1Year) US$3,925389Top
US$ Change (1Year) %280.9378Top
Rel Strength 6 Mo (US$)99621Top

SECTION 5 OTHER DIRECTORS OF MEDIFAST, INC.

Daniel R. Chard, Chief Executive Officer & Director

Michael C. Macdonald, Executive Chairman & Director

Timothy G. Robinson, Chief Financial Officer

Glenn W. Welling, Director

Jeffrey J. Brown, Director

Carl E. Sassano, Independent Director

Charles P. Connolly, Independent Director

Kevin G. Byrnes, Independent Director

Brian Kagen, Executive Vice President

Jason L. Groves, Executive Vice President

SECTION 6 MEDIFAST, INC. ACTIVITIES

Medifast, Inc. (Medifast) is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products. The Company's product lines include weight and disease management, meal replacement, and vitamins primarily manufactured in its modern, the United States Food and Drug Administration (FDA) approved facility in Owings Mills, Maryland. The Company's operations are primarily conducted through five of its wholly owned subsidiaries, Jason Pharmaceuticals, Inc. (Jason), Take Shape for Life, Inc. (TSF), Jason Enterprises, Inc., Jason Properties, LLC and Seven Crondall, LLC. The Company offers a variety of weight and disease management products under the Medifast brand and for select private label customers. It's distribution channels include Medifast Direct, Take Shape for Life, Medifast Weight Control Centers and Medifast Physicians.

SECTION 7 RECENT NEWS ON DIRECTORS

7.1 REPORTED STOCK AWARDS

09 February 2018

Medifast director Carl E. Sassano awarded shares

Medifast (NYSE:MED) director Carl E. Sassano, was awarded 1,280 shares worth $US85,350 on February 07.

09 February 2018

Medifast chief financial officer Timothy G. Robinson awarded shares

Medifast (NYSE:MED) chief financial officer Timothy G. Robinson, was awarded 1,280 shares worth $US85,350 on February 07.

09 February 2018

Medifast chief financial officer Timothy G. Robinson awarded Stock Options

Medifast (NYSE:MED) chief financial officer Timothy G. Robinson, has been awarded Stock Options on 4,500 shares at an exercise price of $US66.68. The transaction date was February 07. The shares last traded at $US66.70.

09 February 2018

Medifast director Jeffrey J. Brown awarded shares

Medifast (NYSE:MED) director Jeffrey J. Brown, was awarded 1,860 shares worth $US124,025 on February 07.

09 February 2018

Medifast director and executive chairman Michael C. Macdonald awarded shares

Medifast (NYSE:MED) director and executive chairman Michael C. Macdonald, was awarded 1,280 shares worth $US85,350 on February 07.

09 February 2018

Medifast director Charles P. Connolly awarded shares

Medifast (NYSE:MED) director Charles P. Connolly, was awarded 640 shares worth $US42,675 on February 07.

09 February 2018

Medifast director Kevin G. Byrnes awarded shares

Medifast (NYSE:MED) director Kevin G. Byrnes, was awarded 1,619 shares worth $US107,955 on February 07.

7.2 SHAREHOLDER VALUE ADDED BY DIRECTORS

01 February 2018

Timothy G. Robinson brings two-bagger value to Medifast

Timothy G. Robinson was appointed CFO of Medifast (NYSE:MED) five years ago on February 01, 2013. The present value of USD1,000 (PV1000) invested on the appointment date is $US2,956, for a capital gain of $US1,793 and dividend reinvested of $US163. In the same period the shares were up 179.3% from $US24.6 to $US68.7.

7.3 RECENT REPORTED SELLING

22 March 2018

Medifast director Charles P. Connolly sells

Medifast (NYSE:MED) Independent Director Charles P. Connolly sold 8,000 shares worth $US727,600 on March 20. The selling price was $US90.95. The shares hit a 13-day high on the day.

19 March 2018

Medifast director Charles P. Connolly sells

Medifast (NYSE:MED) Independent Director Charles P. Connolly sold 7,500 shares worth $US669,825 on March 15. The selling price was $US89.31.

13 March 2018

Medifast director and executive chairman Michael C. Macdonald sells

Medifast (NYSE:MED) Director and Executive Chairman Michael C. Macdonald sold 20,000 shares worth $US1,689,000 on March 08. The selling price was $US84.45.

13 March 2018

Medifast director and executive chairman Michael C. Macdonald sells

Medifast (NYSE:MED) Director and Executive Chairman Michael C. Macdonald sold 20,000 shares worth $US1,779,200 on March 09. The selling price was $US88.96.

Source: www.BuySellSignals.com